Enanta Pharmaceuticals, Inc.
ENTA · Nasdaq · United States
Share price · ENTA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ENTA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-18.6%
- 6 Nov 2026+9.1%
Nothing announced by ENTA that day or the session before.
- 28 Oct 2026-5.2%
- 28 Sep 2026+6.2%
Nothing announced by ENTA that day or the session before.
- 24 Aug 2026+4.7%
Nothing announced by ENTA that day or the session before.
- 16 Jun 2026+5.5%
Nothing announced by ENTA that day or the session before.
- 15 Jun 2026-3.9%
Nothing announced by ENTA that day or the session before.
- 3 Jun 2026-6.6%
Nothing announced by ENTA that day or the session before.
- 12 May 2026-6.0%
- 5 Mar 2026-10.8%
Nothing announced by ENTA that day or the session before.
Share of unusual movement by asset
For each asset, the share of ENTA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | RSV L proteinSmall molecule | Respiratory Syncytial Virus Infection | |
| Phase 2 | RSV N protein (nucleoprotein)Small molecule | Respiratory Syncytial Virus Infection |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2029 (1)
July 2029 (1)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $14M | $22M | $33M+ $156M short-term inv. | $20M-$10.0M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $17M | $19M | $35M+ $129M short-term inv. | $13M-$7.2M operating cash flow | report ↗ |
| 2025-Q4 | $19M | $21M | $37M+ $148M short-term inv. | $12M-$12M operating cash flow | report ↗ |
| 2025-Q2 | $18M | $27M | $45M+ $159M short-term inv. | $18M$18M operating cash flow | report ↗ |
| 2025-Q1 | $15M | $28M | $60M+ $133M short-term inv. | $23M-$13M operating cash flow | report ↗ |
| 2024-Q4 | $17M | $28M | $84M+ $132M short-term inv. | $22M-$17M operating cash flow | report ↗ |
| 2024-Q2 | $18M | $29M | $36M+ $194M short-term inv. | $23M-$15M operating cash flow | report ↗ |
| 2024-Q1 | $17M | $36M | $64M+ $237M short-term inv. | $31M-$29M operating cash flow | report ↗ |
| 2023-Q4 | $18M | $36M | $40M+ $297M short-term inv. | $33M-$25M operating cash flow | report ↗ |
| 2023-Q2 | $19M | $43M | $95M+ $291M short-term inv. | $39M-$32M operating cash flow | report ↗ |
| 2023-Q1 | $18M | $43M | $73M+ $137M short-term inv. | $38M-$14M operating cash flow | report ↗ |
| 2022-Q4 | $24M | $41M | $42M+ $172M short-term inv. | $29M-$36M operating cash flow | report ↗ |
| 2022-Q2 | $19M | $39M | $28M+ $225M short-term inv. | $32M-$30M operating cash flow | report ↗ |
| 2022-Q1 | $19M | $42M | $41M+ $239M short-term inv. | $34M-$26M operating cash flow | report ↗ |
| 2021-Q4 | $28M | $49M | $99M+ $160M short-term inv. | $30M-$13M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $65M | $107M | $32M+ $157M short-term inv. | $20M-$19M operating cash flow | report ↗ |
Enanta Pharmaceuticals reported fiscal 2025 revenue of $65.32M, down 3.4% YoY, and R&D spend of $106.74M, down 18.8% YoY. It ended the year with cash and equivalents of $32.3M and cash, cash equivalents and marketable securities of $188.9M, with a net loss of $81.89M ($3.84 per diluted share) for the twelve months ended September 30, 2025.
Management guided that existing cash, retained royalty cash flows, and proceeds from the October 2025 upsized public offering (approximately $74.8M gross) are expected to fund operations into fiscal 2029. During the period, Enanta reported positive topline data from the Phase 2b RSVHR study of zelicapavir, nominated EPS-3903 as its lead oral STAT6 inhibitor candidate, and selected EDP-978 as an oral KIT inhibitor candidate, with IND filings planned for the first quarter of 2026 and the second half of 2026, respectively. The company also filed a patent infringement action against Pfizer in the European Unified Patent Court regarding Paxlovid.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $68M | $131M | $37M+ $211M short-term inv. | $29M-$79M operating cash flow | report ↗ |
| 2023-FY | $79M | $164M | $85M+ $285M short-term inv. | $33M-$103M operating cash flow | report ↗ |
| 2022-FY | $86M | $165M | $44M+ $205M short-term inv. | $30M-$85M operating cash flow | report ↗ |
| 2021-FY | $97M | $174M | $57M+ $187M short-term inv. | $20M-$70M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 9 sales ($183K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-08 | Rottinghaus Scott T. · Chief Medical Officer | Tax withholding | 1,467 | $13.34 | $20K | Form 4 |
| 2026-03-11 | CARTER BRUCE L A · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
| 2026-03-11 | FOLETTA MARK G · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
| 2026-03-11 | Hata Yujiro S · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
| 2026-03-11 | Peterson Kristine · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
| 2026-03-11 | Russell Lesley · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
| 2026-03-11 | Vance Terry · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
| 2026-02-12 | Luly Jay R. · director, President and CEO | Award / grant | 4,800 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 132 reporting institutions held 26.8M shares ($290.3M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 3,784,055 | $47.7M |
| 2 | BlackRock, Inc. | 3,103,768 | $39.2M |
| 3 | FARALLON CAPITAL MANAGEMENT LLC | 2,871,862 | $36.3M |
| 4 | Deep Track Capital, LP | 1,956,867 | $24.7M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1,178,049 | $14.9M |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 948,904 | $12.0M |
| 7 | Spruce Street Capital LP | 932,598 | $11.8M |
| 8 | MILLENNIUM MANAGEMENT LLC | 882,097 | $11.1M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 725,061 | $9.2M |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 665,258 | $8.4M |
| 11 | STATE STREET CORP | 562,106 | $7.1M |
| 12 | Hillsdale Investment Management Inc. | 435,510 | $5.5M |
| 13 | AQR CAPITAL MANAGEMENT LLC | 313,157 | $4.0M |
| 14 | MORGAN STANLEY | 309,511 | $3.9M |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 294,971 | $3.7M |